A novel multiple-stage antimalarial agent that inhibits protein synthesis

Nature

Volumn 522, Issue 7556, 2015, Pages 315-320

  Baragaña, Beatriz ^a   Hallyburton, Irene ^a   Lee, Marcus C S ^b,c   Norcross, Neil R ^a   Grimaldi, Raffaella ^a   Otto, Thomas D ^c   Proto, William R ^c   Blagborough, Andrew M ^d   Meister, Stephan ^e   Wirjanata, Grennady ^f   Ruecker, Andrea ^d   Upton, Leanna M ^d   Abraham, Tara S ^b   Almeida, Mariana J ^b   Pradhan, Anupam ^g   Porzelle, Achim ^a   Martínez, María Santos ^h   Bolscher, Judith M ⁱ   Woodland, Andrew ^a   Norval, Suzanne ^a   Zuccotto, Fabio ^a   Thomas, John ^a   Simeons, Frederick ^a   Stojanovski, Laste ^a   Osuna Cabello, Maria ^a   Brock, Paddy M ^d   Churcher, Tom S ^d   Sala, Katarzyna A ^d   Zakutansky, Sara E ^d   Jiménez Díaz, María Belén ^h   Sanz, Laura Maria ^h   Riley, Jennifer ^a   Basak, Rajshekhar ^b   Campbell, Michael ^j   Avery, Vicky M ^k   Sauerwein, Robert W ⁱ   Dechering, Koen J ⁱ   Noviyanti, Rintis ^l   Campo, Brice ^m   Frearson, Julie A ^a   Angulo Barturen, Iñigo ^h   Ferrer Bazaga, Santiago ^h   Gamo, Francisco Javier ^h   Wyatt, Paul G ^a   Leroy, Didier ^m   Siegl, Peter ^m   Delves, Michael J ^d   Kyle, Dennis E ^g   Wittlin, Sergio ⁿ   Marfurt, Jutta ^f   Price, Ric N ^f,o   Sinden, Robert E ^d   Winzeler, Elizabeth A ^e   Charman, Susan A ^j   Bebrevska, Lidiya ^m   Gray, David W ^a   Campbell, Simon ^m   Fairlamb, Alan H ^a   Willis, Paul A ^m   Rayner, Julian C ^c   Fidock, David A ^b   Read, Kevin D ^a   Gilbert, Ian H ^a   more..

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b College of Physic and Surg ^*  (United States)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^g UNIVERSITY OF SOUTH FLORIDA   (United States)

^h GLAXOSMITHKLINE   (Spain)

ⁱ Current affiliation: TropIQ Health Sciences   (Netherlands)

^j MONASH UNIVERSITY   (Australia)

^k GRIFFITH UNIVERSITY   (Australia)

^l EIJKMAN INSTITUTE FOR MOLECULAR BIOLOGY   (Indonesia)

^m Medicines for Malaria Venture   (Switzerland)

ⁿ SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^o UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTESUNATE; CYCLOHEXIMIDE; DACTINOMYCIN; DDD 107498; ELONGATION FACTOR 2; GUANOSINE TRIPHOSPHATE; MESSENGER RNA; UNCLASSIFIED DRUG; DDD107498; QUINOLINE DERIVATIVE;

ANTIMALARIAL AGENT; DISEASE CONTROL; DISEASE TRANSMISSION; PARASITE; PROTEIN; PROTOZOAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG SOLUBILITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LIFE CYCLE STAGE; MALE; MOUSE; NONHUMAN; PLASMA HALF LIFE; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RIBOSOME; SINGLE DRUG DOSE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; LIVER; MALARIA; METABOLISM; PARASITOLOGY; PHYSIOLOGY; PLASMODIUM; PLASMODIUM VIVAX;

PLASMODIUM PARASITES;

ANIMALS; ANTIMALARIALS; DRUG DISCOVERY; FEMALE; GENE EXPRESSION REGULATION; LIFE CYCLE STAGES; LIVER; MALARIA; MALE; MODELS, MOLECULAR; PEPTIDE ELONGATION FACTOR 2; PLASMODIUM; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PROTEIN BIOSYNTHESIS; QUINOLINES;

EID: 84934976258     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature14451     Document Type: Article

References (36)

1. World Health Organization. World Malaria Report 2014(World Health Organization, 2014).
2. Ariey, F. et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505, 50-55 (2014).
3. Alonso, P. L. et al. A research agenda for malaria eradication: drugs. PLoS Med. 8, e1000402 (2011).
4. Wells, T. N. C. & Gutteridge, W. E. in Neglected Diseases and Drug Discovery (eds Palmer, M. J. & Wells, T. N. C.) Ch. 1 1-32 (Royal Society of Chemistry, 2012).
5. Brenk, R. et al. Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. ChemMedChem 3, 435-444 (2008).
6. Delves,M. et al.The activities of current anti malarial drugs onthe life cycle stages of Plasmodium: a comparative study with human and rodent parasites. PLoS Med. 9, e1001169 (2012).
7. Russell, B. et al. Determinants of in vitro drug susceptibility testing of Plasmodium vivax. Antimicrob. Agents Chemother. 52, 1040-1045 (2008).
8. Karyana, M. et al. Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum. Malar. J. 7, 148 (2008).
9. Angulo-Barturen, I. et al. Amurinemodel of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes. PLoS ONE 3, e2252 (2008).
10. Sanz, L. M. et al. P. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-action. PLoS ONE 7, e30949 (2012).
11. Burrows, J. N., van Huijsduijnen, R. H., Mohrle, J. J., Oeuvray, C. & Wells, T. N. Designing the next generation of medicines for malaria control and eradication. Malar. J. 12, 187 (2013).
12. Meister, S. et al. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science 334, 1372-1377 (2011).
13. Adjalley, S. H. et al. Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue. Proc. Natl Acad. Sci. USA 108, E1214-E1223 (2011).
14. Bousema, T. & Drakeley, C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin. Microbiol. Rev. 24, 377-410 (2011).
15. Delves, M. J. et al. Male and female Plasmodium falciparum mature gametocytes show different responses to antimalarial drugs. Antimicrob. Agents Chemother. 57, 3268-3274 (2013).
16. Delves, M. J. et al. A high-throughput assay for the identification of malarial transmission-blocking drugs and vaccines. Int. J. Parasitol. 42, 999-1006 (2012).
17. Blagborough, A. M. et al. Transmission-blocking interventions eliminate malaria from laboratory populations. Nature Commun. 4, 1812 (2013).
18. Upton, L.M. et al. Lead clinical and preclinical antimalarial drugs can significantly reduce sporozoite transmission to vertebrate populations. Antimicrob. Agents Chemother. 59, 490-497 (2015).
19. Janse,C. J. et al. High efficiency transfection of Plasmodium berghei facilitates novel selection procedures. Mol. Biochem. Parasitol. 145, 60-70 (2006).
20. Flannery, E. L., Fidock, D. A. & Winzeler, E. A. Using genetic methods to define the targets of compounds with antimalarial activity. J. Med. Chem. 56, 7761-7771 (2013).
21. Rottman, M. et al. Spiroindolones, a potent compound class for the treatment of malaria. Science 329, 1175-1180 (2010).
22. McNamara, C. W. et al. Targeting Plasmodium PI(4)K to eliminate malaria. Nature 504, 248-253 (2013).
23. Miotto, O. et al. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nature Genet. 45, 648-655 (2013).
24. Jorgensen, R., Merrill, A. R. & Andersen, G. R. The life and death of translation elongation factor 2. Biochem. Soc. Trans. 34, 1-6 (2006).
25. Justice, M. C. et al. Elongation factor 2 as a novel target for selective inhibition of fungal protein synthesis. J. Biol. Chem. 273, 3148-3151 (1998).
26. Capa, L., Mendoza, A., Lavandera, J. L., de las Heras, F. G. & Garcia-Bustos, J. F. Translation elongation factor 2 is part of the target for a new family of antifungals. Antimicrob. Agents Chemother. 42, 2694-2699 (1998).
27. Shastry,M. et al.Species-specific inhibitionof fungal protein synthesis by sordarin: identification of a sordarin-specificity region in eukaryotic elongation factor 2. Microbiology 147, 383-390 (2001).
28. Jorgensen, R. et al. Two crystal structures demonstrate large conformational changes in the eukaryotic ribosomal translocase. Nature Struct. Biol. 10, 379-385 (2003).
29. Nkrumah, L. J. et al. Efficient site-specific integration in Plasmodium falciparum chromosomes mediated by mycobacteriophage Bxb1 integrase. Nature Methods 3, 615-621 (2006).
30. Biswas, S. et al. Interaction of apicoplast-encoded elongation factor (EF) EF-Tu with nuclear-encoded EF-Tsmediates translation in the Plasmodiumfalciparumplastid. Int. J. Parasitol. 41, 417-427 (2011).
31. Cox,G. et al. Ribosomeclearance by FusB-type proteinsmediates resistance to the antibiotic fusidic acid. Proc. Natl Acad. Sci. USA 109, 2102-2107 (2012).
32. Ding, X. C., Ubben, D.& Wells, T. N. A framework for assessing the risk of resistance for anti-malarials in development. Malar. J. 11, 292 (2012).
33. Manske, M. et al. Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature 487, 375-379 (2012).
34. Florens, L. et al. A proteomic view of the Plasmodium falciparum life cycle. Nature 419, 520-526 (2002).
35. Jiménez-Díaz, M. B. et al. Quantitative measurement of Plasmodium-infected erythrocytes in murine models of malaria by flow cytometry using bidimensional assessment of SYTO-16 fluorescence. Cytometry A 75, 225-235 (2009).
36. Charman,S.A. et al.Synthetic ozonide drugcandidateOZ439offersnewhopefor a single-dose cure of uncomplicated malaria. Proc. Natl Acad. Sci. USA 108, 4400-4405 (2011).